Stifel analyst Derek Archila lowered his price target for Esperion Therapeutics to $70 from $112 to reflect more conservative assumptions but reiterates a Buy rating on the shares. Even with more conservative forecasts, Esperion is undervalued at these levels, Archila tells investors in a research note. He thinks the stock continues to reflect investor skepticism on the commercial opportunity for bempedoic acid and the company's cash runway. The analyst views bempedoic acid as a "clinically de-risked asset" with two upcoming PDUFA's in February 2020 and believes the cardiovascular outcomes trial design portends a high probability of success. Archila sees a nice entry point into Esperion following the recent selloff and is a buyer of the stock at current levels.